

Bio SB launches antibodies for SARS-CoV-2

April 2021—Bio SB has developed a new panel of SARS-CoV-2 antibodies to identify the COVID-19 virus, its receptors, and its cytokines by immunohistochemistry and immunofluorescence on formalin-fixed, paraffin-embedded biopsies. The antibodies identify ACE2, CD147, and TMPRSS2 receptors and include markers for immune response factors and vascular cells, with the intention to assess the pathological damage caused by COVID-19, cytokine storm syndrome, and coagulopathy, using single and multiplex IHC and immunofluorescence on FFPE tissues.

The company has also released more than 60 IHC antibodies, five TintoFast antibodies, three IHC detection systems, three multiplex IHC detection kits, six tissue and cell-line microarrays, and IHC ancillaries.

[Bio SB](#), 805-692-2768